This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Stocks to Watch: Tiffany, Adobe, Targacept (Update 1)

NEW YORK -- Tiffany (TIF - Get Report) missed analysts' estimates on holiday profit as sales growth fell, hurt by declining sales in Europe and the U.S..

The luxury retailer's fourth-quarter net income fell 1.6% to $178.4 million, or $1.39 a share. Analysts had forecast $1.42 a share.

However, the retailer announced a higher-than-expected earnings forecast for the year. It expects profit of $4.05 a share for the year ending Jan 31, 2013. Analysts are looking for $3.92.

Tiffnay shares were up 3% to $70.75 in premarket trading Tuesday.

The fast food chain Wendy's (WEN) surpassed Burger King as the second biggest fast-food chain.

Wendy's total sales came in at $8.5 billion for 2011, higher than $8.4 billion for its competitor. However, McDonald's remains at the top, with sales of $34.2 billion.

The numbers are from food consulting firm Technomic.

Shares of Wendy's were up 1% to $5.08.

Adobe Systems (ADBE - Get Report), a maker of digital media publishing and marketing applications, posted fiscal first quarter profit in line with analysts' estimates.

Adobe posted non-GAAP profit of $284.5 million, or 57 cents a share, on revenue of $1.045 billion. Analysts were expecting earnings of 57 cents a share on revenue of $1.053 billion.

For the fiscal second quarter ending in May, Adobe forecast non-GAAP earnings of 57 cents to 61 cents a share on revenue ranging from $1.09 billion to $1.14 billion. The current average analysts' view is for a profit of 60 cents a share on revenue of $1.10 billion.

Shares were down 3.9% to $33.15 in premarket trading.

AstraZeneca (AZN)and Targacept (TRGT) announced they will no longer go forward with plans to develop an experimental antidepressant following an unsuccessful late-stage clinical trial. The drug, called TC-5214, failed to show effectiveness compared to placebo when given to depressed patients.

Some analysts had cut their expectations for the drug, so the announcement was not a surprise. Still the drug was a lead product candidate for Targacept.

Shares of the company were plunging almost 13% to $6.40, while shares of AstraZeneca were down 1% to $44.95. (AMZN) agreed to acquire privately held Kiva Systems, a maker of robotic package handling systems for $775 million in cash.

Separately, Amazon will be selling $10 gift cards for $5 on Tuesday to people who visit, its answer to deals sites such as Groupon and LivingSocial, The Associated Press reported.

Shares were down 0.7% to $184.18.

Goldman Sachs (GS)has begun a new round of staff cuts in its trading and investment banking divisions, Reuters reported, citing three sources familiar with the matter. .

Goldman eliminated 2,400 positions last year, and the sources said further reductions are possible as the company continues to reduce costs.

The investment bank's latest round of cuts is part of its annual employee review process.

Shares were off 0.6% to $123.50.

Oracle (ORCL), the database software giant, is expected by analysts Tuesday to earn 56 cents a share in its fiscal third quarter on revenue of $9.02 billion.

Wall Street will be looking to see if the massive expansion of Oracle's sales force that took place in the first half of the company's hiscal year has paid off in the third quarter. Shares were down 0.4% to $29.63.

Walt Disney (DIS) said it expects to record an operating loss of $200 million in its fiscal second quarter ending in March stemming from the poor performance of the movie John Carter.

Shares were down 1% to $43.01.

-- Written by Joseph Woelfel and Chao Deng.

>To contact the writer of this article, click here: Joseph Woelfel

Related links:
Onyx Pharma: An Underdog Worth Buying

Apple Dividend: Fueling New Highs

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ADBE $93.50 0.60%
TIF $70.02 -0.64%
TRGT $1.41 2.17%
AAPL $93.24 -0.41%
FB $117.81 -0.21%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs